First Sentier Group Exits Substantial Shareholding in Mayne Pharma

Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.

First Sentier Group Limited and a wide network of related entities, ultimately linked to Mitsubishi UFJ Financial Group, have lodged a notice that they have ceased to be substantial shareholders in Mayne Pharma Group as of 25 February 2026. The filing, made under Australian Corporations Act disclosure rules, signals that this institutional investor group has reduced its holding below the substantial shareholding threshold, potentially altering Mayne Pharma’s register composition and the influence of this major global financial group on the company.

The change follows an earlier substantial holding notice in January 2026 and reflects adjustments in relevant interests across multiple First Sentier and affiliated vehicles in various jurisdictions. While the notice does not detail the specific transactions or residual stake, it underscores ongoing portfolio rebalancing by large international asset managers and may prompt other investors to reassess Mayne Pharma’s ownership dynamics and liquidity profile.

The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on developing and manufacturing branded and generic medicines. The company primarily serves regulated markets such as Australia and the U.S., with a portfolio spanning oral drug delivery products and contract development and manufacturing services.

Average Trading Volume: 453,583

Technical Sentiment Signal: Sell

Current Market Cap: A$206.4M

For an in-depth examination of MYX stock, go to TipRanks’ Overview page.